Search alternatives:
increase decrease » increased release (Expand Search), increased crash (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
small decrease » small increased (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
small decrease » small increased (Expand Search)
-
1101
-
1102
-
1103
Summary of study eligibility criteria.
Published 2025“…Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.</p><p>Methods</p><p>ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. …”
-
1104
Summary of study participation and feasibility.
Published 2025“…Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.</p><p>Methods</p><p>ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. …”
-
1105
Sociodemographic and economic factors of study subjects, Ethiopia, EDHS 2005–2016 (N = 29,525).
Published 2024Subjects: -
1106
-
1107
Frequency distribution of SOLEC at baseline and follow-ups in WAD grade 2 and WAD grade 3.
Published 2024Subjects: -
1108
-
1109
-
1110
Baseline descriptive characteristics of trial participants (n = 140) with and without dizziness.
Published 2024Subjects: -
1111
Frequency distribution of SOLEC at baseline and follow-ups in the NSEIT and NSE groups.
Published 2024Subjects: -
1112
-
1113
Baseline descriptive characteristics of trial participants with dizziness, by treatment group.
Published 2024Subjects: -
1114
-
1115
-
1116
S1 Graphical abstract -
Published 2024“…A longer diabetes duration was linked to a greater ASI (r = 0.43, p < 0.05), while the AS decreased (r = -0.37, p < 0.05).…”
-
1117
-
1118
-
1119
Effect of ex vivo treatment with rhTGFβ1 or a TGFβ1 inhibitor on monocyte responses to rgE stimulation. Monocytes and NK cells purified from PBMC collected from 10 RZV recipients (demographics in S4 Table) before vaccination (D0) and 90 days post-vaccination (D90) were combined ex vivo and stimulated with VZV-rgE. A subset of D0 monocyte & NK cocultures was also treated with the TGFβ1 inhibitor LY (D0 LY), and a subset of D90 cocultures were supplemented with rhTGFβ1. The graph shows individual data points, means and p values calculated by Friedman test for repeated measures with FDR correction. LY treatment of cells collected on D0 significantly increased their activation to levels similar to D90....
Published 2025“…LY treatment of cells collected on D0 significantly increased their activation to levels similar to D90. …”
-
1120